Maria Paola Costi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2606764/publications.pdf

Version: 2024-02-01

141 papers	3,323 citations	159358 30 h-index	205818 48 g-index
149 all docs	149 docs citations	149 times ranked	4517 citing authors

#	Article	IF	Citations
1	Comprehensive Mechanistic Analysis of Hits from High-Throughput and Docking Screens against Î²-Lactamase. Journal of Medicinal Chemistry, 2008, 51, 2502-2511.	2.9	169
2	The Hippo Pathway and YAP/TAZâ€“TEAD Proteinâ€“Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. Journal of Medicinal Chemistry, 2015, 58, 4857-4873.	2.9	141
3	Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1448-1453.	3.3	135
4	Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. Scientific Reports, 2013, 3, 1035.	1.6	133
5	2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1. ACS Chemical Biology, 2015, 10, 705-714.	1.6	116
6	Structure-based discovery and in-parallel optimization of novelcompetitive inhibitors of thymidylate synthase. Chemistry and Biology, 1999, 6, 319-331.	6.2	103
7	Thymidylate Synthase Structure, Function and Implication in Drug Discovery. Current Medicinal Chemistry, 2005, 12, 2241-2258.	1.2	91
8	Proteinâ€“protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E542-9.	3.3	77
9	Virtual Screening Identification of Nonfolate Compounds, Including a CNS Drug, as Antiparasitic Agents Inhibiting Pteridine Reductase. Journal of Medicinal Chemistry, 2011, 54, 211-221.	2.9	68
10	Structure-Based Optimization of a Non-Î²-lactam Lead Results in Inhibitors That Do Not Up-Regulate Î²-Lactamase Expression in Cell Culture. Journal of the American Chemical Society, 2005, 127, 4632-4639.	6.6	58
11	Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. Drug Resistance Updates, 2015, 23, 20-54.	6.5	57
12	Novel 3â€benzoylâ€2â€piperazinylquinoxaline derivatives as potential antitumor agents. Journal of Heterocyclic Chemistry, 2006, 43, 541-548.	1.4	50
13	Structure-Based Design of Inhibitors Specific for Bacterial Thymidylate Synthase,. Biochemistry, 1999, 38, 1607-1617.	1.2	49
14	Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells. International Journal of Oncology, 2013, 43, 1269-1280.	1.4	47
15	Update on Antifolate Drugs Targets. Current Drug Targets, 2001, 2, 135-166.	1.0	46
16	Structure-based design and in-parallel synthesis of inhibitors of AmpC Î²-lactamase. Chemistry and Biology, 2001, 8, 593-610.	6.2	45
17	Combination of Suboptimal Doses of Inhibitors Targeting Different Domains of LtrMDR1 Efficiently Overcomes Resistance of Leishmania spp. to Miltefosine by Inhibiting Drug Efflux. Antimicrobial Agents and Chemotherapy, 2006, 50, 3102-3110.	1.4	45
18	Homodimeric Enzymes as Drug Targets. Current Medicinal Chemistry, 2010, 17, 826-846.	1.2	45

#	Article	IF	Citations
19	Novel Approaches for Targeting Thymidylate Synthase To Overcome the Resistance and Toxicity of Anticancer Drugs. Journal of Medicinal Chemistry, 2010, 53, 6539-6549.	2.9	45
20	Targeting Class A and C Serine Î²-Lactamases with a Broad-Spectrum Boronic Acid Derivative. Journal of Medicinal Chemistry, 2014, 57, 5449-5458.	2.9	45
21	Structure-Based Selectivity Optimization of Piperidineâ€“Pteridine Derivatives as Potent Leishmania Pteridine Reductase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 8318-8329.	2.9	42
22	Optimizing Cell Permeation of an Antibiotic Resistance Inhibitor for Improved Efficacy. Journal of Medicinal Chemistry, 2007, 50, 5644-5654.	2.9	41
23	Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs. Journal of Medicinal Chemistry, 2016, 59, 7598-7616.	2.9	41
24	Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity. Molecules, 2017, 22, 426.	1.7	39
25	Structural study of phenyl boronic acid derivatives as AmpC Î²-lactamase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3416-3419.	1.0	38
26	Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-Î²-lactamases. Scientific Reports, 2017, 7, 17716.	1.6	35
27	Structure-based studies on species-specific inhibition of thymidylate synthase. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2002, 1587, 206-214.	1.8	34
28	Inhibitor Specificity via Protein Dynamics. Chemistry and Biology, 2003, 10, 1183-1193.	6.2	34
29	Repurposing of Drugs Targeting YAP-TEAD Functions. Cancers, 2018, 10, 329.	1.7	33
30	Designing Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology. Journal of Medicinal Chemistry, 2020, 63, 1908-1928.	2.9	32
31	TRAP1: a viable therapeutic target for future cancer treatments?. Expert Opinion on Therapeutic Targets, 2017, 21, 805-815.	1.5	30
32	X-ray Crystallography Deciphers the Activity of Broad-Spectrum Boronic Acid Î²-Lactamase Inhibitors. ACS Medicinal Chemistry Letters, 2019, 10, 650-655.	1.3	30
33	Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells. European Journal of Pharmacology, 2009, 615, 17-26.	1.7	29
34	Predicting and harnessing protein flexibility in the design of species-specific inhibitors of thymidylate synthase1,21Escherichia coli thymidylate synthase numbering is used unless otherwise noted.2PDB coordinates have been deposited with the RCSB with accession ID: 1JG0.. Chemistry and Biology, 2001, 8, 981-995.	6.2	28
35	The structure ofEnterococcus faecalisthymidylate synthase provides clues about folate bacterial metabolism. Acta Crystallographica Section D: Biological Crystallography, 2012, 68, 1232-1241.	2.5	28
36	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus. European Journal of Medicinal Chemistry, 2017, 135, 467-478.	2.6	28

#	Article	IF	Citations
37	Target-based approaches for the discovery of new antimycobacterial drugs. Drug Discovery Today, 2017, 22, 576-584.	3.2	28
38	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. European Journal of Medicinal Chemistry, 2018, 146, 423-434.	2.6	27
39	Decoding the Structural Basis For Carbapenem Hydrolysis By Class A Î²-lactamases: Fishing For A Pharmacophore. Current Drug Targets, 2016, 17, 983-1005.	1.0	27
40	Label-free fiber optic optrode for the detection of class C Î²-lactamases expressed by drug resistant bacteria. Biomedical Optics Express, 2017, 8, 5191.	1.5	25
41	Virtual screening identifies broad-spectrum Î²-lactamase inhibitors with activity on clinically relevant serine- and metallo-carbapenemases. Scientific Reports, 2020, 10, 12763.	1.6	25
42	Antibacterial Agent Discovery Using Thymidylate Synthase Biolibrary Screening. Journal of Medicinal Chemistry, 2006, 49, 5958-5968.	2.9	24
43	Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery. ACS Omega, 2017, 2, 5666-5683.	1.6	24
44	Phthalein Derivatives as a New Tool for Selectivity in Thymidylate Synthase Inhibition. Journal of Medicinal Chemistry, 1999, 42, 2112-2124.	2.9	23
45	Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (Tb GAPDH) and Trypanosoma cruzi trypanothione reductase (Tc TR) and display trypanocidal activity. European Journal of Medicinal Chemistry, 2017, 141, 138-148.	2.6	23
46	The Inhibition of Extended Spectrum β-Lactamases: Hits and Leads. Current Medicinal Chemistry, 2014, 21, 1405-1434.	1.2	23
47	Optimization of Peptides That Target Human Thymidylate Synthase to Inhibit Ovarian Cancer Cell Growth. Journal of Medicinal Chemistry, 2014, 57, 1355-1367.	2.9	22
48	Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides. Journal of Proteome Research, 2014, 13, 5250-5261.	1.8	22
49	Current Treatments to Control African Trypanosomiasis and One Health Perspective. Microorganisms, 2022, 10, 1298.	1.6	22
50	Quinoxaline chemistry. Part 11. 3-Phenyl-2 [phenoxy- and phenoxymethyl]-6(7) or 6,8-substituted quinoxalines and N-[4-(6(7)-substituted or 6,8-disubstituted-3-phenylquinoxalin-2-yl)hydroxy or hydroxymethyl]benzoylglutamates. Synthesis and evaluation of in vitro anticancer activity and enzymatic inhibitory activity against dihydrofolate reductase and thymidylate synthase. Il Farmaco, 1998, 53, 480-493.	0.9	21
51	Hotspots in an Obligate Homodimeric Anticancer Target. Structural and Functional Effects of Interfacial Mutations in Human Thymidylate Synthase. Journal of Medicinal Chemistry, 2015, 58, 3572-3581.	2.9	21
52	Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case. ChemMedChem, 2016, 11, 1653-1666.	1.6	21
53	Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections. Journal of Medicinal Chemistry, 2019, 62, 3989-4012.	2.9	21
54	Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 7773-7785.	1.4	20

#	Article	IF	Citations
55	Permeation through the Cell Membrane of a Boron-Based Î²-Lactamase Inhibitor. PLoS ONE, 2011, 6, e23187.	1.1	20
56	Inhibitor of Ovarian Cancer Cells Growth by Virtual Screening: A New Thiazole Derivative Targeting Human Thymidylate Synthase. Journal of Medicinal Chemistry, 2012, 55, 10272-10276.	2.9	20
57	Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds. European Journal of Medicinal Chemistry, 2017, 126, 1129-1135.	2.6	20
58	Comparative mapping of on-targets and off-targets for the discovery of anti-trypanosomatid folate pathway inhibitors. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 3215-3230.	1.1	20
59	Thymidylate synthase inhibition: A structure-based rationale for drug design. , 1998, 18, 21-42.		19
60	Virtual Screening and X-ray Crystallography Identify Non-Substrate Analog Inhibitors of Flavin-Dependent Thymidylate Synthase. Journal of Medicinal Chemistry, 2016, 59, 9269-9275.	2.9	19
61	Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR). European Journal of Medicinal Chemistry, 2018, 155, 229-243.	2.6	19
62	THEORETICAL STUDY OF ELECTRONIC SPECTRA AND PHOTOPHYSICS OF URACIL DERIVATIVES. Photochemistry and Photobiology, 1990, 52, 361-374.	1.3	18
63	Quinoxaline chemistry. Part 15. 4-[2-Quinoxalylmethylenimino]-benzoylglutamates and -benzoates, 4-[2-quinoxalylmethyl-N-methylamino]-benzoylglutamates as analogues of classical antifolate agents. Synthesis, elucidation of structures and in vitro evaluation of antifolate and anticancer activities. Il Farmaco, 2003, 58, 51-61.	0.9	18
64	Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. European Journal of Medicinal Chemistry, 2019, 183, 111676.	2.6	18
65	Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform. SLAS Discovery, 2019, 24, 346-361.	1.4	18
66	Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines. Gynecologic Oncology, 2010, 117, 202-210.	0.6	17
67	Structural Comparison of Enterococcus faecalis and Human Thymidylate Synthase Complexes with the Substrate dUMP and Its Analogue FdUMP Provides Hints about Enzyme Conformational Variabilities. Molecules, 2019, 24, 1257.	1.7	17
68	Improving Specificity vs Bacterial Thymidylate Synthases throughN-Dansyl Modulation of Didansyltyrosine. Journal of Medicinal Chemistry, 2005, 48, 913-916.	2.9	16
69	Dimerâ€“monomer equilibrium of human thymidylate synthase monitored by fluorescence resonance energy transfer. Protein Science, 2010, 19, 1023-1030.	3.1	16
70	Enhanced anti-hyperproliferative activity of human thymidylate synthase inhibitor peptide by solid lipid nanoparticle delivery. Colloids and Surfaces B: Biointerfaces, 2015, 136, 346-354.	2.5	16
71	Molecular basis for covalent inhibition of glyceraldehydeâ€3â€phosphate dehydrogenase by a 2â€phenoxyâ€1,4â€naphthoquinone small molecule. Chemical Biology and Drug Design, 2017, 90, 225-235.	1.5	16
72	Conformational analysis of phthalein derivatives acting as thymidylate synthase inhibitors by means of 1H NMR and quantum chemical calculations. Bioorganic and Medicinal Chemistry, 1996, 4, 1783-1794.	1.4	14

#	Article	IF	Citations
73	Aza-boronic acids as non-Î²-lactam inhibitors of AmpC-Î²-lactamase. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3979-3983.	1.0	14
74	Sequenceâ€Based Identification of Specific Drug Target Regions in the Thymidylate Synthase Enzyme Family. ChemMedChem, 2008, 3, 392-401.	1.6	14
75	In Silico Identification and In Vitro Evaluation of Natural Inhibitors of Leishmania major Pteridine Reductase I. Molecules, 2017, 22, 2166.	1.7	14
76	Structural Insights into the Development of Cycloguanil Derivatives as Trypanosoma brucei Pteridine-Reductase-1 Inhibitors. ACS Infectious Diseases, 2019, 5, 1105-1114.	1.8	14
77	Synthesis of N-(5,7-diamino-3-phenyl-quinoxalin-2-yl)-3,4,5-substituted anilines and N-[4[(5,7-diamino-3-phenylquinoxalin-2-yl)amino]benzoyl]-l-glutamic acid diethyl ester: Evaluation of in vitro anti-cancer and anti-folate activities. European Journal of Medicinal Chemistry, 2008, 43, 189-203.	2.6	13
78	Identification of the Binding Modes ofN-Phenylphthalimides Inhibiting Bacterial Thymidylate Synthase through X-Ray Crystallography Screening. Journal of Medicinal Chemistry, 2011, 54, 5454-5467.	2.9	13
79	Folic Acidâ€“Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting. Journal of Medicinal Chemistry, 2021, 64, 3204-3221.	2.9	13
80	Development of a Focused Library of Triazoleâ€Linked Privilegedâ€Structureâ€Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections. ChemMedChem, 2018, 13, 678-683.	1.6	12
81	Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. BMC Cancer, 2018, 18, 1267.	1.1	12
82	pH-Promoted Release of a Novel Anti-Tumour Peptide by â€œStealthâ€•Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells. Pharmaceutical Research, 2018, 35, 206.	1.7	12
83	Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth. Vitamins and Hormones, 2018, 107, 473-513.	0.7	12
84	Cyclization reactions of 1,3â€dibromopropanâ€2â€ol, 2,3â€dibromopropanâ€1â€ol and 1â€bromomethyloxirane with 6â€aminoâ€2,3â€dihydroâ€2â€thioxoâ€4(1H)â€pyrimidinone. Journal of Heterocyclic Chemistry, 1991, 28, 891-898.	1.4	11
85	Design, synthesis and biological evaluation of non-covalent AmpC Î²-lactamases inhibitors. Medicinal Chemistry Research, 2017, 26, 975-986.	1.1	11
86	The structure ofCryptococcus neoformansthymidylate synthase suggests strategies for using target dynamics for species-specific inhibition. Acta Crystallographica Section D: Biological Crystallography, 2005, 61, 1320-1334.	2.5	10
87	Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells. Amino Acids, 2012, 42, 641-653.	1.2	10
88	Biochemical effects of riluzole on Leishmania parasites. Experimental Parasitology, 2013, 133, 250-254.	0.5	10
89	Translational repression of thymidylate synthase by targeting its mRNA. Nucleic Acids Research, 2013, 41, 4159-4170.	6.5	10
90	Internalization and Stability of a Thymidylate Synthase Peptide Inhibitor in Ovarian Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 10551-10556.	2.9	10

#	Article	IF	Citations
91	Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology. Scientific Reports, 2016, 6, 27198.	1.6	10
92	The Future of Drug Development for Neglected Tropical Diseases: How the European Commission Can Continue to Make a Difference. Trends in Parasitology, 2017, 33, 581-583.	1.5	10
93	Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase. Pharmaceuticals, 2021, 14, 636.	1.7	10
94	Separation, structural determination and biological evaluation of the thymidylate synthase inhibitor 3,3â€Ÿdiâ€(4â€²â€hydroxyphenyl)â€6(7)â€chloroâ€1â€oxoâ€1 H,3Hâ€naphtho[1,8â€cd]pyran. Journal of Heterocyclic Chemistry, 1999, 36, 1043-1048.	1.4	9
95	2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes. European Journal of Medicinal Chemistry, 2014, 75, 169-183.	2.6	9
96	Alanine Mutants of the Interface Residues of Human Thymidylate Synthase Decode Key Features of the Binding Mode of Allosteric Anticancer Peptides. Journal of Medicinal Chemistry, 2015, 58, 1012-1018.	2.9	9
97	Conveying a newly designed hydrophilic anti-human thymidylate synthase peptide to cisplatin resistant cancer cells: are pH-sensitive liposomes more effective than conventional ones?. Drug Development and Industrial Pharmacy, 2017, 43, 465-473.	0.9	9
98	The 1,10-Phenanthroline Ligand Enhances the Antiproliferative Activity of DNA-Intercalating Thiourea-Pd(II) and -Pt(II) Complexes Against Cisplatin-Sensitive and -Resistant Human Ovarian Cancer Cell Lines. International Journal of Molecular Sciences, 2019, 20, 6122.	1.8	9
99	Naphthalimido derivatives as antifolate thymidylate synthase inhibitors. European Journal of Medicinal Chemistry, 1996, 31, 1011-1016.	2.6	8
100	ortho-Halogen naphthaleins as specific inhibitors of Lactobacillus casei thymidylate synthase. Conformational properties and biological activity. Bioorganic and Medicinal Chemistry, 2003, 11, 951-963.	1.4	8
101	New thymidylate synthase inhibitors induce apoptosis in melanoma cell lines. Toxicology in Vitro, 2007, 21, 240-248.	1.1	8
102	Ligand-based discovery of N-(1,3-dioxo-1H,3H-benzo[de]isochromen-5-yl)-carboxamide and sulfonamide derivatives as thymidylate synthase A inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 663-668.	1.0	8
103	2â€²-Deoxyuridine 5â€²-Monophosphate Substrate Displacement in Thymidylate Synthase through 6-Hydroxy-2H-naphtho[1,8-bc]furan-2-one Derivatives. Journal of Medicinal Chemistry, 2013, 56, 9356-9360.	2.9	8
104	Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign. European Journal of Medicinal Chemistry, 2020, 189, 112047.	2.6	8
105	Multitarget, Selective Compound Design Yields Potent Inhibitors of a Kinetoplastid Pteridine Reductase 1. Journal of Medicinal Chemistry, 2022, 65, 9011-9033.	2.9	8
106	Structures and Reactivities of 1-Oxo-cycloalkan-2-ylideneacetic Acids. A 1H NMR, Modelling and Photochemical Study. Tetrahedron, 2000, 56, 7561-7571.	1.0	7
107	Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer. Frontiers in Pharmacology, 2018, 9, 454.	1.6	7
108	Proteinâ€“Protein Interaction Inhibitors: Case Studies on Small Molecules and Natural Compounds. , 2013, , 31-60.		7

#	Article	IF	Citations
109	Sesquiterpene Lactones with Dual Inhibitory Activity against the Trypanosoma brucei Pteridine Reductase 1 and Dihydrofolate Reductase. Molecules, 2022, 27, 149.	1.7	7
110	Design and characterization of a mutation outside the active site of human thymidylate synthase that affects ligand binding. Protein Engineering, Design and Selection, 2010, 23, 81-89.	1.0	6
111	Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines. Investigational New Drugs, 2012, 30, 1484-1492.	1.2	6
112	Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth. Journal of Medicinal Chemistry, 2018, 61, 7374-7380.	2.9	6
113	Excited-state intramolecular proton transfer in a bioactive flavonoid provides fluorescence observables for recognizing its engagement with target proteins. Photochemical and Photobiological Sciences, 2019, 18, 2270-2280.	1.6	6
114	High-resolution crystal structure of Trypanosoma brucei pteridine reductase 1 in complex with an innovative tricyclic-based inhibitor. Acta Crystallographica Section D: Structural Biology, 2020, 76, 558-564.	1.1	6
115	The structural roles of conserved Pro196, Pro197 and His199 in the mechanism of thymidylate synthase. Protein Engineering, Design and Selection, 2003, 16, 607-614.	1.0	5
116	SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent. ACS Medicinal Chemistry Letters, 2019, 10, 528-533.	1.3	5
117	Optimization of N â€alkylation in the Synthesis of Methotrexate and Pteridineâ€based Derivatives Under Microwaveâ€irradiation. ChemistrySelect, 2019, 4, 4429-4433.	0.7	5
118	A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 4452.	1.8	5
119	Theoretical analysis of the addition of hydroxylamine to uracil and 5-fluorouracil as a model for the thymidylate synthase reaction. Computational and Theoretical Chemistry, 1995, 343, 1-9.	1.5	4
120	Constrained Dansyl Derivatives Reveal Bacterial Specificity of Highly Conserved Thymidylate Synthases. ChemBioChem, 2008, 9, 779-790.	1.3	4
121	Anchors away. Nature, 2009, 458, 840-841.	13.7	4
122	Scaffolds and Biological Targets Avenue to Fight Against Drug Resistance in Leishmaniasis. Annual Reports in Medicinal Chemistry, 2018, 51, 39-95.	0.5	4
123	Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth. Molecules, 2019, 24, 3493.	1.7	4
124	New Insights into Bioactive Compounds from the Medicinal Plant Spathodea campanulata P. Beauv. and Their Activity against Helicobacter pylori. Antibiotics, 2020, 9, 258.	1.5	4
125	Asparagine 229 Mutants of Thymidylate Synthase Catalyze the Methylation of 3-Methyl-2â€˜-deoxyuridine 5â€˜-Monophosphateâ€. Biochemistry, 1996, 35, 3944-3949.	1.2	3
126	Evidence of Destabilization of the Human Thymidylate Synthase (hTS) Dimeric Structure Induced by the Interface Mutation Q62R. Biomolecules, 2019, 9, 134.	1.8	3

#	Article	IF	Citations
127	Design, Synthesis and Antiparasitic Evaluation of Click Phospholipids. Molecules, 2021, 26, 4204.	1.7	3
128	Pharmacological and toxicological evaluation of a new series of thymidylate synthase inhibitors as anticancer agents. Anticancer Research, 2006, 26, 3499-504.	0.5	3
129	Targeting the Trypanosomatidic Enzymes Pteridine Reductase and Dihydrofolate Reductase. , 2013, , 445-472.		2
130	Design, Synthesis and Structureâ€"Activity Relationships of a Phenotypic Small Library against Protozoan Infections. Proceedings (mdpi), 2017, 1, 648.	0.2	2
131	Structural and Functional Characterization of the Human Thymidylate Synthase (hTS) Interface Variant R175C, New Perspectives for the Development of hTS Inhibitors. Molecules, 2019, 24, 1362.	1.7	2
132	Structural Bases for the Synergistic Inhibition of Human Thymidylate Synthase and Ovarian Cancer Cell Growth by Drug Combinations. Cancers, 2021, 13, 2061.	1.7	2
133	Repurposing the Trypanosomatidic GSK Kinetobox for the Inhibition of Parasitic Pteridine and Dihydrofolate Reductases. Pharmaceuticals, 2021, 14, 1246.	1.7	2
134	Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups. International Journal of Gynecological Cancer, 2022, 32, 799-803.	1.2	2
135	A condensed thiadiazolo-pyrimidine as a new efficient fluorophore. Theoretical and experimental investigation of the electronic spectra and photophysics. Journal of Photochemistry and Photobiology A: Chemistry, 1994, 77, 227-236.	2.0	1
136	Intrinsic Fluorescence of the Active and the Inactive Functional Forms of Human Thymidylate Synthase. ChemBioChem, 2021, 22, 1800-1810.	1.3	1
137	Identification of a Quinone Derivative as a YAP/TEAD Activity Modulator from a Repurposing Library. Pharmaceutics, 2022, 14, 391.	2.0	1
138	Quinoxaline Chemistry. Part 15. 4-[2-Quinoxalylmethylenimino]-benzoylglutamates and -benzoates, 4-[2-Quinoxalylmethyl-N-methylamino]-benzoylglutamates as Analogues of Classical Antifolate Agents. Synthesis, Elucidation of Structures and in vitro Evaluation of Antifolate and Anticancer Activities.. ChemInform, 2003, 34, no.	0.1	0
139	Opening Opportunities for New Drugs Against Neglected Diseases. ChemMedChem, 2008, 3, 371-373.	1.6	0
140	Drug resistance in ovarian cancer: Biomarkers and treatments. Gynecologic Oncology, 2010, 117, 149-151.	0.6	0
141	Intrinsic Fluorometric Reporters of Pteridine Reductase 1, a Target for Antiparasitic Agents. Physchem, 2022, 2, 131-144.	0.5	0